AEAlice Elphick

Alice Elphick

*This is an algorithmically generated author record based on publicly available information.

Alice Elphick has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impaired glucose tolerance and mild diabetes induce β-cell dysfunction in mice

    by Elizabeth Haythorne, Matthew Lloyd, Chris A. Smith, Martijn van de Bunt, Maria Rohm, Alice Elphick, Malgorzata Cyranka, Fiona M. Gribble, Frank Reimann, Frances M. Ashcroft

    Severe chronic hyperglycaemia ( > 15 mM) causes impaired glycolytic and mitochondrial metabolism in pancreatic β-cells, leading to dramatically reduced insulin secretion and content. However, patients with type 2 diabetes often experience many years of reduced β-cell function and impaired glucose tolerance preceding diabetes diagnosis. It is postulated that β-cell function may be compromised by relatively small changes in glycaemia, initiating a gradual decline that underlies diabetes progression. We therefore investigated the extent to which impaired glucose tolerance and chronic mild hyperglycaemia are detrimental to β-cells. We show that chronic elevation of blood glucose of just 2-3 mM is sufficient to impair β-cell function, causing marked changes in metabolic gene expression and reducing insulin content, metabolic enzyme activity, mitochondrial oxidative phosphorylation and insulin secretion. Smaller but significant changes are produced by impaired glucose tolerance. These findings demonstrate that altered β-cell metabolism is an early event in type 2 diabetes development and highlight a need for therapeutic intervention during prediabetes.


  • Open Access

    Contrasting Effects of Chronic Glucokinase Activation and Inhibition on Pancreatic Beta‐Cell Function

    by Matthew Lloyd, Natascia Vedovato, Samuel J. Mullan, Alice Elphick, Aerin J. Dumenil, Chantal Rufer, Alexandra C. Title, Burcak Yesildag, Elizabeth Haythorne, Frances M. Ashcroft

    Chronic hyperglycaemia impairs insulin secretion by disrupting beta‐cell metabolism and reducing expression of insulin. These changes are mediated by glucose metabolites downstream of glucokinase. We hypothesized that chronically enhancing glucokinase activity at low glucose would mimic the effects of glucotoxicity and, conversely, that reducing glucokinase activity would prevent the deleterious effects of chronic hyperglycaemia. Human islet microtissues or INS‐1 cells were cultured at low or high glucose for 2 weeks (islets) or 48 h (INS‐1 cells) in the presence or absence of either a glucokinase activator (MK‐0941 or dorzagliatin) or a glucokinase inhibitor (mannoheptulose). We measured changes in glucose‐stimulated insulin secretion, insulin content, glycogen content, gene expression, and oxygen consumption. Chronic glucokinase activation in low‐glucose‐cultured islet microtissues and INS‐1 cells downregulated insulin secretion and content, impaired mitochondrial metabolism, and altered metabolic gene expression, to the same extent as high‐glucose culture. Conversely, reduction of glucokinase activity in high‐glucose‐cultured islet microtissues by mannoheptulose prevented the changes produced by chronic hyperglycaemia. Moreover, the effects of chronic hyperglycaemia on insulin secretion and metabolic gene expression (but not insulin content) were largely reversed by subsequent inhibition of glucokinase. Chronic glucokinase activation in euglycaemia thus mimics the effects of chronic hyperglycaemia, whereas partial inhibition of glucokinase in hyperglycaemia restores normal beta‐cell function. This explains why, in the long term, glucokinase activators are ineffective at controlling glycaemia in type 2 diabetes, and demonstrates that normalizing glucokinase activity can prevent and reverse chronic glucose toxicity.